Bone marrow angiogenesis and progression in multiple myeloma - PubMed (original) (raw)
Bone marrow angiogenesis and progression in multiple myeloma
A Vacca et al. Br J Haematol. 1994 Jul.
Abstract
Tumour growth is angiogenesis-dependent. We found a high correlation between the extent of bone marrow angiogenesis, evaluated as microvessel area, and the proliferating (S-phase) fraction of marrow plasma cells, evaluated as labelling index (LI), in patients with multiple myeloma (MM) and in those with monoclonal gammopathies of undetermined significance (MGUS). Angiogenesis itself was significantly associated with active as opposed to non-active MM and MGUS. The highest microvessel area accompanied rapidly progressive MM with the highest LI. When a cut-off value of 2% or greater of the microvessel area was used, most patients with active MM were classified correctly. The risk of active disease in patients with MM increased in parallel with the microvessel area. A causal relationship between plasma cell growth, activity phase in MM and marrow angiogenesis is suggested. Since angiogenesis proceeds in step with the enlargement of plasma cell tumours and the activity phase in MM, its measurement could be a useful prognostic marker in patients with plasma cell proliferative disorders.
Similar articles
- Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma.
Vacca A, Ribatti D, Presta M, Minischetti M, Iurlaro M, Ria R, Albini A, Bussolino F, Dammacco F. Vacca A, et al. Blood. 1999 May 1;93(9):3064-73. Blood. 1999. PMID: 10216103 - Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies.
Vacca A, Ribatti D, Roncali L, Dammacco F. Vacca A, et al. Leuk Lymphoma. 1995 Dec;20(1-2):27-38. doi: 10.3109/10428199509054750. Leuk Lymphoma. 1995. PMID: 8750620 Review. - Microvessel overexpression of aquaporin 1 parallels bone marrow angiogenesis in patients with active multiple myeloma.
Vacca A, Frigeri A, Ribatti D, Nicchia GP, Nico B, Ria R, Svelto M, Dammacco F. Vacca A, et al. Br J Haematol. 2001 May;113(2):415-21. doi: 10.1046/j.1365-2141.2001.02738.x. Br J Haematol. 2001. PMID: 11380407 - Bone marrow angiogenesis in patients with active multiple myeloma.
Vacca A, Ribatti D, Roccaro AM, Frigeri A, Dammacco F. Vacca A, et al. Semin Oncol. 2001 Dec;28(6):543-50. doi: 10.1016/s0093-7754(01)90022-3. Semin Oncol. 2001. PMID: 11740807 Review. - Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis.
Rajkumar SV, Mesa RA, Fonseca R, Schroeder G, Plevak MF, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Gertz MA, Kyle RA, Russell SJ, Greipp PR. Rajkumar SV, et al. Clin Cancer Res. 2002 Jul;8(7):2210-6. Clin Cancer Res. 2002. PMID: 12114422
Cited by
- Highlighting the role of long non-coding RNA (LncRNA) in multiple myeloma (MM) pathogenesis and response to therapy.
Al-Hawary SIS, Jasim SA, Altalbawy FMA, Hjazi A, Jyothi SR, Kumar A, Eldesoqui M, Rasulova MT, Sinha A, Zwamel AH. Al-Hawary SIS, et al. Med Oncol. 2024 Jun 7;41(7):171. doi: 10.1007/s12032-024-02392-8. Med Oncol. 2024. PMID: 38849654 Review. - The Tumor Microenvironment in Classic Hodgkin's Lymphoma in Responder and No-Responder Patients to First Line ABVD Therapy.
Tamma R, Ingravallo G, Gaudio F, d'Amati A, Masciopinto P, Bellitti E, Lorusso L, Annese T, Benagiano V, Musto P, Specchia G, Ribatti D. Tamma R, et al. Cancers (Basel). 2023 May 17;15(10):2803. doi: 10.3390/cancers15102803. Cancers (Basel). 2023. PMID: 37345141 Free PMC article. - Anti-Angiogenic Activity of Drugs in Multiple Myeloma.
Saltarella I, Altamura C, Campanale C, Laghetti P, Vacca A, Frassanito MA, Desaphy JF. Saltarella I, et al. Cancers (Basel). 2023 Mar 27;15(7):1990. doi: 10.3390/cancers15071990. Cancers (Basel). 2023. PMID: 37046651 Free PMC article. Review. - Does the pursuit of scientific excellence serve or hamper translational medical research: an historical perspective from hematological malignancies.
Bunce CM, Khanim FL, Drayson MT. Bunce CM, et al. Blood Cancer J. 2022 Oct 7;12(10):142. doi: 10.1038/s41408-022-00738-x. Blood Cancer J. 2022. PMID: 36202796 Free PMC article. Review. - What's Old is New: The Past, Present and Future Role of Thalidomide in the Modern-Day Management of Multiple Myeloma.
Costa BA, Mouhieddine TH, Richter J. Costa BA, et al. Target Oncol. 2022 Jul;17(4):383-405. doi: 10.1007/s11523-022-00897-8. Epub 2022 Jun 30. Target Oncol. 2022. PMID: 35771402 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical